A new fructose-free, resistant-starch type IV-enriched enteral formula improves glycaemic control and cardiovascular risk biomarkers when administered for six weeks to elderly diabetic patients

Artículo original

Año: 2017

Garcia, MDM; Garcia-Rodriguez, CE; Rico, MD; Aguilera, CM; Perez-Rodriguez, M; Perez-de-la-Cruz, AJ; Gil, A

Título: NUTRICION HOSPITALARIA

• Q4